A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. - Wikidata - awgldk - TriplyDB

A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma.

A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma.

http://www.wikidata.org/entity/Q33418737

about

Therapeutic options in peripheral T cell lymphoma Romidepsin for the Treatment of Peripheral T-Cell Lymphoma Pruritus Reduction with Systemic Anti-lymphoma Treatments in Patients with Cutaneous T Cell Lymphoma: A Narrative Review Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents Histone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancy Highly Diverse Efficacy of Salvage Treatment Regimens for Relapsed or Refractory Peripheral T-Cell Lymphoma: A Systematic Review Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.Gemcitabine, dexamethasone, and cisplatin (GDP) as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma-not otherwise specified.Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience.Cutaneous T-Cell Lymphoma: A Review with a Focus on Targeted Agents.New developments in the treatment of peripheral T-cell lymphoma - role of Belinostat.The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma.Novel therapeutic agents for cutaneous T-Cell lymphoma.Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management.First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation.Long-term complete remission with belinostat in a patient with chemotherapy refractory peripheral T-cell lymphoma.Fingerprinting of neurotoxic compounds using a mouse embryonic stem cell dual luminescence reporter assay Belinostat for Relapsed or Refractory Peripheral T-Cell Lymphoma.HDAC inhibitor-based therapies: can we interpret the code?Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.Ibrutinib in B lymphoid malignancies.Histone deacetylase inhibitors and epigenetic regulation in lymphoid malignancies.Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma.Targeting histone deacetylases in T-cell lymphoma.Selective histone deacetylase small molecule inhibitors: recent progress and perspectives.Treatment approaches of hard-to-treat non-Hodgkin lymphomas.A phase I study to determine the pharmacokinetics and urinary excretion of belinostat and metabolites in patients with advanced solid tumors.Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma Differential Regulation of Telomerase Reverse Transcriptase Promoter Activation and Protein Degradation by Histone Deacetylase Inhibition.Changes in cardiac Nav1.5 expression, function, and acetylation by pan-histone deacetylase inhibitors.Recent advances in understanding and managing T-cell lymphoma.Survival following salvage therapy for primary refractory peripheral T-cell lymphomas (PTCL).Efficacy of hydralazine and valproate in cutaneous T-cell lymphoma, a phase II study.New Therapies and Immunological Findings in Cutaneous T-Cell Lymphoma.Comparison of interleukin-2-inducible kinase (ITK) inhibitors and potential for combination therapies for T-cell lymphoma Histone Deacetylase Inhibitors and Diabetic Kidney Disease Histone deacetylase 6 in cancer Next-Generation Drugs and Probes for Chromatin Biology: From Targeted Protein Degradation to Phase Separation

P2860

Q26748857-7E704CC2-0F41-41F1-8864-A9DC9C51675E Q26785732-D3DB2C12-D6F0-4DAD-8C87-C63E3633BE76 Q28075343-0664E9D8-225F-44FF-B165-84BE6FA9DB9A Q28075606-ABF0F287-52CC-412E-835E-5C4C4D614A8D Q28082536-5E0E35E5-BE22-42E5-AD8E-57A22BC737AA Q28554530-B10C76E0-F41D-4CC5-BB5D-0A6216FADC21 Q30936712-076DE778-9097-4088-B6B6-17AAD7502212 Q33423816-119F0797-0331-4854-BDDE-27E293E88CA7 Q33436867-C133AEB4-E5DB-41CF-9055-DC9E9CAD69B2 Q34307446-F24FABA7-610C-4F8E-A23E-57F0B5954082 Q34516083-3F424E4F-9C3B-4E85-9377-40ED4A5B50AF Q35703714-645C684B-E5F1-480B-967B-85098202FBF7 Q35859219-B337C46D-302A-47D6-BECD-BFD618B4B898 Q36161365-EB010CA7-41A8-41A9-BBDE-BFC94188C10F Q36470196-89E2E592-EFE6-435B-A8F9-02CD07DAA9F1 Q37271019-A6E78545-BCA8-477A-9091-BEEB027AFD00 Q37355651-F8500FCC-53AE-4B80-BD62-A21C73852526 Q37578338-5194B26E-76A6-43D2-BFC7-34BFA7330A7C Q37579991-78CD6E81-6D83-4CF9-AC82-B5AD60501FA5 Q38058971-4E597037-6BAA-4A52-8F03-AE99E4C6D41C Q38515832-BB72AC0A-81E5-413E-900F-080C6074B752 Q38545545-8550A8E2-B4BB-4244-A3AB-1337D1D684BF Q38595978-10BDF103-A95D-4B8F-9C4A-D42D987FFC45 Q38752460-E077CD94-389F-43BF-8F6F-7A699CD71C4B Q38765451-F4459CCA-FBF7-4166-AEB0-AD982ADD5837 Q38998630-B9352F59-B8B5-4647-97AB-9507262D2F12 Q39062353-1DAC29AB-AE6C-4CFB-B25B-9472E73102C0 Q39091822-7E07C2D7-DC5D-4363-9858-553BCB7166E5 Q39287526-785A3C36-DABC-429F-B10B-310817D658DD Q39955238-0DEBA398-0116-40B0-8681-65B9F4548989 Q40388317-2138F2EC-5219-47E7-B78B-C1775E331DC5 Q42784091-31CD12E2-9F2D-4CD5-91C9-E4730E52674C Q47131247-E3BBE554-170F-4DA1-A16E-F2A18FAC86DF Q48197102-BFB0C02C-0906-44EF-ABB0-5B5D8015CB6E Q50853522-DB7B268B-9056-4D9F-8255-39D903270479 Q55334211-10E68033-B313-49D3-BD9C-C1BF18D2C96B Q58705889-52C91BFD-EB49-4998-8C5B-B7BBB502E5B4 Q58762435-9FB9DDFC-3D1D-48D7-ADA3-FBF68239848A Q58768571-C66DDD86-AFD9-4A45-BA3E-1EDABFCA5FA5 Q58798742-EF709501-FD21-4572-881F-DD95CC4133CA

P2860

A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma.

http://www.wikidata.org/entity/Q33418737

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

A Phase II trial of Belinostat ...... or cutaneous T-cell lymphoma.

@ast

A Phase II trial of Belinostat ...... or cutaneous T-cell lymphoma.

@en

type

label

A Phase II trial of Belinostat ...... or cutaneous T-cell lymphoma.

@ast

A Phase II trial of Belinostat ...... or cutaneous T-cell lymphoma.

@en

prefLabel

A Phase II trial of Belinostat ...... or cutaneous T-cell lymphoma.

@ast

A Phase II trial of Belinostat ...... or cutaneous T-cell lymphoma.

@en

P1433

Q33418737-8B23E22F-D5E5-4BAA-896E-25E00B41935D

P1476

Q33418737-B0C4F109-DE0B-4381-BB4E-70553B91F2D9

P2093

Q33418737-03778F70-B2A9-4780-8470-5C5299B34859

Q33418737-052C12C4-8CBF-4745-95B2-FAA99147E77E

Q33418737-33FB3CFE-172C-4472-A51C-9966E45210D0

Q33418737-3C4B0E3E-1BE2-4E7C-BB4F-D10540011BC7

Q33418737-420EA5CE-2E17-4E43-A7DD-EFF3A89D3D42

Q33418737-46F5DE9A-4D5F-498C-9AFD-88506A0AB648

Q33418737-47DB781F-68D9-40B4-9FF7-B676D284CF9C

Q33418737-66533628-A4B4-4619-A868-BFD611884BE3

Q33418737-7208FDF0-8F23-4CC9-8191-9C85DBB48264

Q33418737-7A5A7326-24E8-4F90-97F3-926AB3BF77F1

P2860

Q33418737-147F89A8-5B19-457E-886B-59B97D0E5E39

Q33418737-228D6C03-7CDB-4D80-B908-1EBAF84FF093

Q33418737-2B33567D-6CFE-43E5-A35B-18BEEC086F25

Q33418737-3A49112B-AD55-432B-AB01-329DADA60F12

Q33418737-43D979DB-1510-4E81-A8C9-63ADB960003D

Q33418737-47A1EEB6-4C06-436C-8D9A-79FA1911F793

Q33418737-483BF7F9-6A7C-489D-95FD-1567FD440BFF

Q33418737-4BA918D4-6521-4977-BEAE-82D0A1C81BD8

Q33418737-8070B149-360D-474A-9F08-20CB6C26DAEC

Q33418737-890DFB16-9DE2-4CD2-9D27-168908FE055F

P304

Q33418737-2218E9D0-18BA-46BA-AD80-DD7BFE74E651

P31

Q33418737-ABA596EE-D0B6-4022-9332-8DF3765C4449

P356

Q33418737-878A065A-8261-4B6E-9E69-42D8ED0EDB27

P407

Q33418737-5A59BD48-DA91-4181-A199-481499A6468E

P433

Q33418737-352634AD-525F-4F48-9562-5D5FA5FB620B

P478

Q33418737-9DBD4B34-EC02-4B71-B7DC-299078B0245F

P50

Q33418737-86D2B7C0-78BA-4AE5-8919-A6D34ADA9E4F

Q33418737-8BBE9C82-B902-4844-94A1-294105A14060

P577

Q33418737-B75D02DF-BD48-46FB-B6F8-8C47A5AFA023

P5875

Q33418737-98B5A7F7-E8EE-4A3E-831C-DF5BCE2C7B74

P698

Q33418737-45CE122B-B350-45FA-92E9-3FC13C859281

P921

Q33418737-864CB0D2-9F4A-4F65-AF0A-0D1549895E0C

Q33418737-D02DCBF6-C3DB-42B6-93B3-6FDE0317F9C7

P356

P1433

British Journal of Haematology

P1476

A Phase II trial of Belinostat ...... or cutaneous T-cell lymphoma.

@en

P2093

Arnuparp Lekhakula

http://www.w3.org/2001/XMLSchema#string

Brad Pohlman

http://www.w3.org/2001/XMLSchema#string

Dina Ben-Yehuda

http://www.w3.org/2001/XMLSchema#string

Eric D Jacobsen

http://www.w3.org/2001/XMLSchema#string

Francine Foss

http://www.w3.org/2001/XMLSchema#string

Gajanan Bhat

http://www.w3.org/2001/XMLSchema#string

Guy Laurent

http://www.w3.org/2001/XMLSchema#string

Kenneth B Hymes

http://www.w3.org/2001/XMLSchema#string

Lee F Allen

http://www.w3.org/2001/XMLSchema#string

Madeleine Duvic

http://www.w3.org/2001/XMLSchema#string

P2860

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.

A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours

Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study

Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy.

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.

WHO-EORTC classification for cutaneous lymphomas.

International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes.

Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications

Novel therapies in peripheral T-cell lymphomas.

P304

811-819

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BJH.13222

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

168

http://www.w3.org/2001/XMLSchema#string

P50

Marie Beylot-Barry

P577

2014-11-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

268528122

http://www.w3.org/2001/XMLSchema#string

P698

25404094

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial